Skip to Main Content

JERUSALEM — The chief executive of Teva Pharmaceuticals on Thursday said he is making “strong progress” on the company’s restructuring plan, even as the company posted a huge loss and forecast a challenging 2018.

In an interview, CEO Kare Schultz said he remained confident about the company’s long-term prospects, laying out a two-year turnaround timeline and predicting a “clear move upward” in 2020.


The restructuring has marked a stunning setback in Israel for a company seen as a national source of pride.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!